Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial's Second Cohort